CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that it has been granted a United States patent (# 7,335,371) entitled “Combinations for the treatment of inflammatory disorders” with broad composition of matter and method of use claims covering combinations of tricyclic antidepressants (TCA) and glucocorticosteroids. This patent contains claims covering CRx-191, the Company’s lead topical dermatology product candidate, and other product candidates, and will expire in 2022, unless extended. The full patent can be viewed on the United States Patent and Trademark Office website under published documents: http://portal.uspto.gov/external/portal/pair.
